A review of the pharmacokinetics, efficacy and safety of high-purity factor X for the prophylactic treatment of hereditary factor X deficiency
Open Access
- 1 May 2022
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 28 (4) , 523-531
Abstract
Introduction Hereditary factor X (FX) deficiency (FXD) is a rare autosomal recessive bleeding disorder. Plasma-derived FX (pdFX) is a high-purity FX concentrate approved in the United States and Europe for the treatment and prophylaxis of bleeding episodes and for peri-operative management in patients with hereditary FXD (HFXD). Aim To review pharmacokinetic dosing, efficacy, and safety data for pdFX as routine prophylaxis for HFXD. Methods Summary of the published pharmacokinetic and safety data from TEN01, TEN02, TEN05, and real-world publications of pdFX for prophylaxis. Results Pharmacokinetic modelling data from the phase 3 TEN01 study supported administration of pdFX 25 IU/kg twice weekly for routine prophylaxis in adolescents/adults (aged >= 12 years). Results from nine paediatric patients in the phase 3 TEN02 study and eight adolescents/adults (aged >= 12 years) in the retrospective data-collection TEN05 study, along with real-world evidence, showed that routine prophylaxis with pdFX approximate to 40 IU/kg twice weekly in patients aged pdFX was well tolerated in clinical studies, with no new safety signals identified during routine prophylactic use. Based on current evidence, it is recommended that routine prophylaxis with pdFX be initiated at 25 IU/kg twice weekly in adults/adolescents >= 12 years of age, and at a dosage of 40 IU/kg twice weekly in children = 5 IU/dl.Keywords
This publication has 17 references indexed in Scilit:
- Plasma-derived human factor X concentrate for on-demand and perioperative treatment in factor X-deficient patients: pharmacology, pharmacokinetics, efficacy, and safetyExpert Opinion on Drug Metabolism & Toxicology, 2016
- Experience of a new high‐purity factor X concentrate in subjects with hereditary factor X deficiency undergoing surgeryHaemophilia, 2016
- Efficacy, safety and pharmacokinetics of a new high‐purity factor X concentrate in subjects with hereditary factor X deficiencyHaemophilia, 2016
- Pharmacokinetics of a high‐purity plasma‐derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiencyHaemophilia, 2016
- Guideline for the diagnosis and management of the rare coagulation disordersBritish Journal of Haematology, 2014
- Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentratesHaemophilia, 2014
- Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severityJournal of Thrombosis and Haemostasis, 2012
- Efficacy of prophylaxis and genotype‐phenotype correlation in patients with severe Factor X deficiency in IranHaemophilia, 2011
- The rare coagulation disorders – review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' OrganisationHaemophilia, 2004
- Prophylactic treatment of severe factor X deficiency with prothrombin complex concentrateHaemophilia, 2001